Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 3
2015 3
2016 3
2017 7
2018 3
2019 5
2020 6
2021 4
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Liquid biopsy in colorectal cancer: Onward and upward.
Torresan S, de Scordilli M, Bortolot M, Di Nardo P, Foltran L, Fumagalli A, Guardascione M, Ongaro E, Puglisi F. Torresan S, et al. Among authors: ongaro e. Crit Rev Oncol Hematol. 2024 Feb;194:104242. doi: 10.1016/j.critrevonc.2023.104242. Epub 2023 Dec 20. Crit Rev Oncol Hematol. 2024. PMID: 38128627 Review.
Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives.
de Scordilli M, Michelotti A, Zara D, Palmero L, Alberti M, Noto C, Totaro F, Foltran L, Guardascione M, Iacono D, Ongaro E, Fasola G, Puglisi F. de Scordilli M, et al. Among authors: ongaro e. Crit Rev Oncol Hematol. 2023 Jun;186:104013. doi: 10.1016/j.critrevonc.2023.104013. Epub 2023 Apr 26. Crit Rev Oncol Hematol. 2023. PMID: 37116817 Review.
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
The SAFFO Study: Sex-Related Prognostic Role and Cut-Off Definition of Monocyte-to-Lymphocyte Ratio (MLR) in Metastatic Colorectal Cancer.
Lisanti C, Basile D, Garattini SK, Parnofiello A, Corvaja C, Cortiula F, Bertoli E, Ongaro E, Foltran L, Casagrande M, Di Nardo P, Cardellino GG, Fasola G, Buonadonna A, Pella N, Aprile G, Puglisi F. Lisanti C, et al. Among authors: ongaro e. Cancers (Basel). 2022 Dec 28;15(1):175. doi: 10.3390/cancers15010175. Cancers (Basel). 2022. PMID: 36612170 Free PMC article.
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome.
Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. Michelotti A, et al. Among authors: ongaro e. Cells. 2021 Aug 9;10(8):2034. doi: 10.3390/cells10082034. Cells. 2021. PMID: 34440803 Free PMC article. Review.
Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer.
Garattini SK, Basile D, Bonotto M, Ongaro E, Porcu L, Corvaja C, Cattaneo M, Andreotti VJ, Lisanti C, Bertoli E, Pelizzari G, Iacono D, Miolo G, Cardellino GG, Buonadonna A, Aprile G, Fasola G, Puglisi F, Pella N. Garattini SK, et al. Among authors: ongaro e. Cancers (Basel). 2021 Jul 13;13(14):3504. doi: 10.3390/cancers13143504. Cancers (Basel). 2021. PMID: 34298718 Free PMC article.
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.
Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, Berardi R, Cardellino GG, De Manzoni G, De Vita F, Di Maio M, Fornaro L, Frassineti GL, Granetto C, Iachetta F, Lonardi S, Murialdo R, Ongaro E, Pucci F, Ratti M, Silvestris N, Smiroldo V, Spallanzani A, Strippoli A, Tamberi S, Tamburini E, Zaniboni A, Di Bartolomeo M, Cremolini C, Sposito C, Mazzaferro V, Pietrantonio F. Raimondi A, et al. Among authors: ongaro e. Cancers (Basel). 2021 Jun 7;13(11):2839. doi: 10.3390/cancers13112839. Cancers (Basel). 2021. PMID: 34200267 Free PMC article.
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.
Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M. Cremolini C, et al. Among authors: ongaro e. J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225. Online ahead of print. J Clin Oncol. 2020. PMID: 32816630 Free article.
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer.
Garattini SK, Bonotto M, Porcu L, Ongaro E, Gerratana L, Basile D, Parnofiello A, Pelizzari G, Cortiula F, Corvaja C, Casagrande M, Cardellino GG, Buonadonna A, Aprile G, Puglisi F, Fasola G, Pella N. Garattini SK, et al. Among authors: ongaro e. Future Oncol. 2020 Nov;16(32):2645-2660. doi: 10.2217/fon-2020-0270. Epub 2020 Aug 10. Future Oncol. 2020. PMID: 32776795
38 results